A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2.

Journal Article (Journal Article)

Full Text

Duke Authors

Vlahovic, Gordana

Cited Authors

Knox, J; Cheng, A; Cleary, S; Galle, P; Kokudo, N; Lencioni, R; Park, J; Zhou, J; Mann, H; Morgan, S; Liu, X; Chin, S; Vlahovic, G; Fan, J

Published Date

July 2019

Published In

Ann Oncol

Volume / Issue

30 Suppl 4 /

Start / End Page

iv59 - iv60

PubMed ID

32085222

Electronic International Standard Serial Number (EISSN)

1569-8041

Digital Object Identifier (DOI)

10.1093/annonc/mdz155.216

Language

eng

Conference Location

England